Conditions: Migraine Headache
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 1473
Healthy volunteers: no

Brief summary:
A study to evaluate rizatriptan/MK0462 (5 and 10 mg) for the treatment of acute migraine attack and treatment of up to two headache recurrences compared to placebo.

The long term extension study which pools patients from MK0462-022, -025, and -029 is described in NCT01286207.

Detailed description:

Arms:
arm 1: None arm 2: None arm 3: None

Interventions: intervention 1: rizatriptan benzoate (MK0462) intervention 2: Comparator: placebo
Intervention descriptions: intervention 1: Single dose administration of 5 or 10 mg oral tablet of rizatriptan, taken immediately upon development of acute/severe migraine headache. intervention 2: Placebo to rizatriptan

Protocol document: